Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) provides access to the company’s regulatory disclosures as an Exchange Act registrant with common stock listed on the NYSE American. These filings document key aspects of Apimeds’ evolution as a clinical-stage biopharmaceutical company focused on non-opioid, biologic-based pain therapies and its merger with MindWave Innovations Inc., an institutional Digital Asset Treasury solutions provider.
Among the most informative documents are the company’s current reports on Form 8-K, which describe material events such as the entry into an Agreement and Plan of Merger with MindWave Innovations Inc., Apimeds Merger Sub, Inc., and Lokahi Therapeutics, Inc.; the structure of the merger consideration, including common and preferred stock; and the resulting ownership percentages. Other 8-K filings detail amendments to bylaws to allow shareholder action by written consent, changes to executive employment agreements, and departures or removals of directors, along with the composition of the remaining board.
Filings also address capital structure and financing arrangements, including a Securities Purchase Agreement for senior convertible notes, amendments to that agreement, and a certificate of designation for Series A Convertible Preferred Stock. An amended Form 8-K (8-K/A) explains corrections to the merger agreement and to the number of preferred shares designated, illustrating how Apimeds uses SEC filings to clarify and update previously reported terms.
Investors reviewing APUS filings can trace the company’s initial public offering on the NYSE American, its status as an emerging growth company, and subsequent PIPE financing associated with the MindWave merger, as described across registration statements and current reports. The filings also reference the preparation of an Information Statement under Section 14(c) of the Exchange Act to describe the merger, related stockholder approvals, reverse stock split, and equity incentive plan changes.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight the main points of lengthy filings, such as 8-Ks and related exhibits. Users can quickly understand how each filing relates to Apimeds’ Apitox development program, its non-opioid pain-management focus, its integration of digital-asset treasury capabilities, and its governance and capital structure decisions, without reading every page in full.
Apimeds Pharmaceuticals US, Inc. notified the SEC that it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 on time and expects to file within the fifteen‑day grace period provided by Rule 12b-25.
The Company says it needs additional time to complete its year-end financial statements and for its independent auditor to finish the review and audit.
Apimeds Pharmaceuticals US, Inc. is implementing a 1-for-10 reverse stock split of its issued and outstanding common stock. Stockholders holding a majority of the voting power approved the action by written consent on December 1, 2025.
The company plans to file a charter amendment in Delaware on or about March 25, 2026, and has set 12:01 a.m. Eastern Time on March 26, 2026 as the effective time. Apimeds expects its common stock to begin trading on a split-adjusted basis on the NYSE American under the symbol APUS on March 26, 2026, with a new CUSIP of 03771D201.
Apimeds Pharmaceuticals US, Inc. is notifying stockholders that consenting holders holding approximately 51% approved several corporate actions on December 1, 2025, including conversions of Series A preferred and convertible notes, a proposed 1-for-10 reverse stock split (board may elect to implement or abandon), an amendment to reduce par value from $0.01 to $0.001, an increase of shares available under the 2024 Equity Incentive Plan to 2,096,679, and adoption of a 2025 Equity Incentive Plan.
The approvals were taken in connection with a merger that closed on December 1, 2025, after which MindWave became a direct wholly owned subsidiary and MindWave holders, on an as-converted, fully diluted basis, will collectively hold 90.9% of the Company’s equity. The Preferred Stock Conversion and Notes Conversion will not be effected unless NYSE American approves the Company’s new listing application. The Information Statement was first mailed on or about March 5, 2026 and the actions become effective on or about March 25, 2026 (at least twenty calendar days after mailing).
Apimeds Pharmaceuticals US, Inc. filed Amendment No. 2 to its Form 8-K to add financial disclosures related to a previously reported reverse merger. The amendment supplies unaudited consolidated financial statements as of September 30, 2025, audited statements for the years ended March 31, 2025 and 2024, and unaudited pro forma consolidated financial information required by Item 9.01. It does not report new events after the original 8-K and does not change earlier disclosures except for providing these financial exhibits.
Apimeds Pharmaceuticals US, Inc. filed Amendment No. 2 to its current report to add full financial statements and unaudited pro forma information for its reverse merger with MindWave Innovations Inc. MindWave is a digital-asset-focused business holding $132.3 million of digital assets at fair value as of September 30, 2025, mainly Bitcoin, Tether and its native NILA token.
MindWave reported net income of $55.9 million for the year ended March 31, 2025, driven by unrealized and realized gains on digital assets, and a net loss of $6.6 million for the six months ended September 30, 2025 as digital asset values moved the other way. The pro forma data treat MindWave as the accounting acquirer, with its prior shareholders holding 90.9% of Apimeds’ equity on an as-converted basis at closing, highlighting that the combined company is effectively MindWave’s public listing vehicle.
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri report a 9.99% beneficial stake in Apimeds Pharmaceuticals US, Inc. They collectively beneficially own 1,397,021 shares of common stock issuable upon conversion of certain convertible notes, subject to a 9.99% ownership blocker, as of December 31, 2025.
The reported percentage is based on 12,575,983 Apimeds common shares outstanding as of November 12, 2025, plus 1,397,021 shares issuable from the notes. Each reporting person has sole voting and dispositive power over the 1,397,021 shares and certifies a passive, ordinary-course investment intent.